Summary of common side effects during use of Zilucoplan

Zilucoplan is a new small molecule complement C5 inhibitor that is mainly used to treat adult patients with myasthenia gravis (MG; rare disease) who are AChR antibody-positive (AChR-Ab+). It blocks the activation process of C5 in the complement system and prevents the formation of membrane attack complex (MAC) at the neuromuscular junction, thereby alleviating neuromuscular signal transmission disorders and improving myasthenia symptoms. Although the therapeutic effects of zeleptide are widely recognized, as an immune system modulator, it is still possible to produce a series of adverse reactions and side effects.

One of the most common side effects during treatment with zeleptide is injection site reaction, such as localized redness, pain, itching, or induration. Since the drug is a subcutaneous injection that is injected once a day, long-term use may cause skin irritation, so the injection site needs to be changed regularly to reduce local discomfort. In most cases, these reactions are mild and resolve on their own within a few hours.

In addition, some patients may experience general discomfort such as headache, fatigue, nausea, or mild diarrhea. Such symptoms are usually related to initial adaptation to medication, and most are reversible reactions that do not affect continued treatment. However, if the symptoms continue to worsen or affect the quality of life, the doctor should be notified as soon as possible to evaluate whether the dose needs to be adjusted or the drug discontinued for observation.

Because zeleptide acts on the immune complement system, it may also cause a slight increase in the risk of infection. In particular, the potential risk of meningococcal infection is of concern, so before using this drug, it is recommended that patients complete meningococcal vaccination and maintain close observation during the medication. Once infectious symptoms such as persistent fever, headache, and neck stiffness occur, you should seek medical attention immediately.

Rarely, patients have reported allergic reactions or drug intolerance issues, which often require discontinuation of the drug.

Reference materials:https://www.drugs.com/zilucoplan.html